EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis

Jihye Lee iD, Shinhee Park iD, Hee-Young Yoon iD

Therapeutic Advances in Respiratory Disease · 2025-10 · 19

DOI: 10.1177/17534666251390672 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025-11. Verfasst von Jihye Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonology and Allergy, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of …. Hauptthemen laut MEDLINE: Quality of Life, Lung Diseases, Interstitial, Antifibrotic Agents, Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Soonchunhyang University, korea health industry development institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interstitial lung disease (ILD) leads to progressive lung function decline and significant respiratory symptoms. Although antifibrotic agents preserve lung function and reduce mortality in ILD, their impact on health-related quality of life (HRQoL) remains unclear.

Objectives

We aimed to evaluate whether antifibrotic agents improve HRQoL and their effectiveness in treating HRQoL-related symptoms in patients with ILD.

Design

Systematic review and meta-analysis. Data sources and methods: A literature search was conducted using MEDLINE, EMBASE, and the Cochrane Library from inception to August 25, 2025. The search included terms related to ILD, antifibrotic agents, and measures of HRQoL. HRQoL outcomes were assessed using the St. George’s Respiratory Questionnaire (SGRQ), including total and domain scores. Data were pooled using a random-effects model, with outcomes reported as mean differences (MD) or relative risks (RR) and heterogeneity evaluated using the I² statistic.

Results

A total of 13 randomized controlled trials were included. Antifibrotic agents showed significant improvement in SGRQ scores, particularly in the symptom (MD: −2.59, 95% confidence interval [CI]: −4.56 to −0.61; I ² = 32%) and activity (MD: -2.88, 95% CI: –4.82 to –0.94; I ² = 34%) domains. Antifibrotics reduced the rate of cough (RR: 0.77, 95% CI: 0.64–0.94; I ² = 0%) and dyspnea (RR: 0.71, 95% CI: 0.56 to 0.89; I ² = 0%). However, fatigue was frequently observed in patients treated with antifibrotics (RR: 1.48, 95% CI: 1.20–1.83; I ² = 0%) compared with the non-antifibrotic group. Most trials were judged to have low-to-moderate risk of bias, and the certainty of evidence was rated very low for total SGRQ scores but low to moderate for domain-specific outcomes and symptoms.

Conclusion

Antifibrotic agents may improve HRQoL and reduce dyspnea and cough in patients with ILD, but the certainty of evidence is low, and they may increase fatigue, requiring careful monitoring.

Trial registration

The study protocol was registered in PROSPERO (CRD42023450917).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeLung Diseases, InterstitialAntifibrotic AgentsLungHumansTreatment OutcomeRandomized Controlled Trials as TopicRecovery of Function

Stichwörter der Autor:innen

antifibrotic agentshealth-related quality of lifeidiopathic pulmonary fibrosisinterstitial lung diseasepatient-reported outcome measures

Substanzen

Antifibrotic Agents

Autor:innen und Institutionen

  • Division of Pulmonology and Allergy, Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea.
  • Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, Republ…

ORCID-Profile: Jihye Lee, Shinhee Park, Hee-Young Yoon

Förderung

  • Soonchunhyang University
  • korea health industry development institute

Zitieren

APA

Lee, J., Park, S., & Yoon, H. Y. (2025). Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis. Therapeutic Advances in Respiratory Disease, 19. https://doi.org/10.1177/17534666251390672

Vancouver

Lee J, Park S, Yoon HY. Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis. Therapeutic Advances in Respiratory Disease. 2025;19. doi:10.1177/17534666251390672

BibTeX
@article{Lee2025,
  author = {Lee, Jihye and Park, Shinhee and Yoon, Hee-Young},
  title = {Effectiveness of antifibrotics on health-related quality of life in patients with interstitial lung disease: a systematic review and meta-analysis},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2025},
  volume = {19},
  doi = {10.1177/17534666251390672}
}
Kostenlos starten →